Generate Biomedicines (NASDAQ:GENB) Shares Up 7.9% – Time to Buy?

Generate Biomedicines Inc (NASDAQ:GENB)’s share price shot up 7.9% on Monday . The stock traded as high as $16.15 and last traded at $15.6410. 225,803 shares were traded during trading, a decline of 63% from the average session volume of 616,535 shares. The stock had previously closed at $14.49.

Analysts Set New Price Targets

GENB has been the subject of a number of research analyst reports. HC Wainwright lifted their target price on shares of Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Cantor Fitzgerald assumed coverage on Generate Biomedicines in a report on Tuesday, March 24th. They set an “overweight” rating for the company. Wall Street Zen downgraded Generate Biomedicines from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Zacks Research raised Generate Biomedicines to a “hold” rating in a research note on Wednesday, March 25th. Finally, Morgan Stanley raised their target price on Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, May 14th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $25.40.

Generate Biomedicines Stock Performance

The firm’s fifty day moving average is $13.54.

Generate Biomedicines (NASDAQ:GENB) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.59).

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.